Abstract
Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs’ pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.
Keywords: Pharmacogenomics, aspirin, P2Y12 antagonists, vitamin K antagonists, direct oral anticoagulants, response variability, personalized medicine, network biology
Current Pharmaceutical Design
Title:Pharmacogenomics of Oral Antithrombotic Drugs
Volume: 22 Issue: 13
Author(s): Flavia Storelli, Youssef Daali, Jules Desmeules, Jean-Luc Reny and Pierre Fontana
Affiliation:
Keywords: Pharmacogenomics, aspirin, P2Y12 antagonists, vitamin K antagonists, direct oral anticoagulants, response variability, personalized medicine, network biology
Abstract: Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs’ pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.
Export Options
About this article
Cite this article as:
Storelli Flavia, Daali Youssef, Desmeules Jules, Reny Jean-Luc and Fontana Pierre, Pharmacogenomics of Oral Antithrombotic Drugs, Current Pharmaceutical Design 2016; 22 (13) . https://dx.doi.org/10.2174/1381612822666151208122845
DOI https://dx.doi.org/10.2174/1381612822666151208122845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Effect of Fenofibrate on the Concentration and Relative Distribution of LDL Subfractions in Patients with Combined Dyslipidemia
Letters in Drug Design & Discovery Mass Spectrometry-Based Metabolic Profiling
Current Metabolomics Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Perioperative Safety of Warfarin Therapy and Reversal
Current Drug Safety Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab
Current Medicinal Chemistry The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine Metabolism in Patients with Rheumatoid Arthritis: Resting Energy Expenditure, Physical Activity and Diet-Induced Thermogenesis. Invited Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Pharmacokinetic Interactions Between Herbal Medicines and Prescribed Drugs: Focus on Drug Metabolic Enzymes and Transporters
Current Drug Metabolism The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets A Comprehensive Review on Recent Developments in the Field of Biological Applications of Potent Pyrazolines Derived from Chalcone Precursors
Letters in Drug Design & Discovery Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Insights into Immunophilin Structure and Function
Current Medicinal Chemistry Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Current Cardiology Reviews Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews